NAGE vs. LRN
NAGE (Niagen Bioscience, Inc) and LRN (Stride, Inc.) are both stocks. NAGE operates in Biotechnology (Healthcare), while LRN operates in Education & Training Services (Consumer Defensive). Over the past 10 years, NAGE returned -5.02%/yr vs 23.78%/yr for LRN. At a 0.12 correlation, their price movements are largely independent.
Performance
NAGE vs. LRN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NAGE achieves a -45.91% return, which is significantly lower than LRN's 53.44% return. Over the past 10 years, NAGE has underperformed LRN with an annualized return of -5.02%, while LRN has yielded a comparatively higher 23.78% annualized return.
NAGE
- 1D
- -2.82%
- 1M
- -30.22%
- YTD
- -45.91%
- 6M
- -47.32%
- 1Y
- -70.80%
- 3Y*
- 31.29%
- 5Y*
- -17.39%
- 10Y*
- -5.02%
LRN
- 1D
- 1.76%
- 1M
- 7.99%
- YTD
- 53.44%
- 6M
- 62.77%
- 1Y
- -30.11%
- 3Y*
- 33.48%
- 5Y*
- 28.19%
- 10Y*
- 23.78%
NAGE vs. LRN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NAGE Niagen Bioscience, Inc | -45.91% | 19.89% | 270.98% | -14.88% | -55.08% | -22.08% | 11.37% | 25.66% | -41.67% | 77.64% |
LRN Stride, Inc. | 53.44% | -37.53% | 75.05% | 89.80% | -6.15% | 56.99% | 4.32% | -17.91% | 55.91% | -7.34% |
Correlation
The correlation between NAGE and LRN is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Jul 16, 2008 | 0.12 |
Fundamentals
NAGE:
$290.91M
LRN:
$4.74B
NAGE:
$0.22
LRN:
$9.68
NAGE:
15.78
LRN:
10.29
NAGE:
0.13
LRN:
0.26
NAGE:
2.25
LRN:
1.90
NAGE:
3.53
LRN:
2.89
NAGE:
$130.42M
LRN:
$2.54B
NAGE:
$83.83M
LRN:
$972.24M
NAGE:
$13.37M
LRN:
$424.60M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NAGE vs. LRN — Risk / Return Rank
NAGE
LRN
NAGE vs. LRN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Niagen Bioscience, Inc (NAGE) and Stride, Inc. (LRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NAGE | LRN | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -1.36 | -0.45 | -0.90 |
Sortino ratioReturn per unit of downside risk | -2.54 | -0.08 | -2.46 |
Omega ratioGain probability vs. loss probability | 0.70 | 0.98 | -0.28 |
Calmar ratioReturn relative to maximum drawdown | -0.93 | -0.47 | -0.46 |
Martin ratioReturn relative to average drawdown | -1.36 | -0.73 | -0.63 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NAGE | LRN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -1.36 | -0.45 | -0.90 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.23 | 0.55 | -0.78 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.06 | 0.48 | -0.55 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.03 | 0.15 | -0.18 |
Drawdowns
NAGE vs. LRN - Drawdown Comparison
The maximum NAGE drawdown since its inception was -97.00%, which is greater than LRN's maximum drawdown of -81.41%. Use the drawdown chart below to compare losses from any high point for NAGE and LRN.
Loading charts...
Drawdown Indicators
| NAGE | LRN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.00% | -81.41% | -15.59% |
Max Drawdown (1Y)Largest decline over 1 year | -76.13% | -64.07% | -12.06% |
Max Drawdown (3Y)Largest decline over 3 years | -76.13% | -64.07% | -12.06% |
Max Drawdown (5Y)Largest decline over 5 years | -88.71% | -64.07% | -24.64% |
Max Drawdown (10Y)Largest decline over 10 years | -93.65% | -64.07% | -29.58% |
Current DrawdownCurrent decline from peak | -81.64% | -41.33% | -40.31% |
Average DrawdownAverage peak-to-trough decline | -75.72% | -36.27% | -39.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 52.25% | 41.53% | +10.72% |
Volatility
NAGE vs. LRN - Volatility Comparison
Niagen Bioscience, Inc (NAGE) has a higher volatility of 20.67% compared to Stride, Inc. (LRN) at 7.85%. This indicates that NAGE's price experiences larger fluctuations and is considered to be riskier than LRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NAGE | LRN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.67% | 7.85% | +12.82% |
Volatility (6M)Calculated over the trailing 6-month period | 34.51% | 23.81% | +10.70% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.25% | 67.31% | -15.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 77.24% | 51.38% | +25.86% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 80.01% | 49.23% | +30.78% |
Dividends
NAGE vs. LRN - Dividend Comparison
Neither NAGE nor LRN has paid dividends to shareholders.
Financials
NAGE vs. LRN - Financials Comparison
This section allows you to compare key financial metrics between Niagen Bioscience, Inc and Stride, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NAGE vs. LRN - Profitability Comparison
NAGE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported a gross profit of 19.98M and revenue of 31.47M. Therefore, the gross margin over that period was 63.5%.
LRN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Stride, Inc. reported a gross profit of 231.56M and revenue of 629.87M. Therefore, the gross margin over that period was 36.8%.
NAGE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported an operating income of 1.58M and revenue of 31.47M, resulting in an operating margin of 5.0%.
LRN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Stride, Inc. reported an operating income of 129.08M and revenue of 629.87M, resulting in an operating margin of 20.5%.
NAGE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported a net income of 6.32M and revenue of 31.47M, resulting in a net margin of 20.1%.
LRN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Stride, Inc. reported a net income of 248.49M and revenue of 629.87M, resulting in a net margin of 39.5%.
Frequently Asked Questions
NAGE and LRN have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NAGE has higher volatility (20.67%) compared to LRN (7.85%). In terms of maximum drawdown, NAGE dropped -97.00% vs LRN's -81.41%.
LRN currently has the higher Sharpe Ratio (-0.45 vs -1.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NAGE and LRN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer